Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Regitine

×

Overview

What is Regitine?

Regitine, phentolamine mesylate for injection, USP, is an antihypertensive, available in vials for intravenous and intramuscular administration. Each vial contains phentolamine mesylate USP, 5 mg, and mannitol USP, 25 mg, in sterile, lyophilized form.

Phentolamine mesylate is 4,5-dihydro-2-[N-(-hydroxyphenyl)-N-(-methylphenyl) aminomethyl]-1-imidazole 1:1 methanesulfonate, and its structural formula is

Phentolamine mesylate for injection, USP, is a white or off-white, odorless crystalline powder with a molecular weight of 377.46. Its solutions are acid to litmus. It is freely soluble in water and in alcohol, and slightly soluble in chloroform. It melts at about 178ºC.



What does Regitine look like?



What are the available doses of Regitine?

Sorry No records found.

What should I talk to my health care provider before I take Regitine?

Sorry No records found

How should I use Regitine?

Sorry No records found


What interacts with Regitine?

Sorry No Records found


What are the warnings of Regitine?

Sorry No Records found


What are the precautions of Regitine?

Sorry No Records found


What are the side effects of Regitine?

Sorry No records found


What should I look out for while using Regitine?

Myocardial infarction, history of myocardial infarction, coronary insufficiency, angina, or other evidence suggestive of coronary artery disease; hypersensitivity to phentolamine or related compounds.

Myocardial infarction, cerebrovascular spasm, and cerebrovascular occlusion have been reported to occur following the administration of Regitine, usually in association with marked hypotensive episodes.

For screening tests in patients with hypertension, the generally available urinary assay of catecholamines or other biochemical assays have largely replaced the Regitine and other pharmacological tests for reasons of accuracy and safety. None of the chemical or pharmacological tests is infallible in the diagnosis of pheochromocytoma. The Regitine blocking test is not the procedure of choice and should be reserved for cases in which additional confirmatory evidence is necessary and the relative risks involved in conducting the test have been considered.


What might happen if I take too much Regitine?


How should I store and handle Regitine?

VialsThe reconstituted solution should be used upon preparation and should not be stored.Store between 15ºC and 30ºC (59ºF-86ºF).665490                                     C98-25 (Rev. 6/98)Distributed byNovartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936©1998 NovartisVialsThe reconstituted solution should be used upon preparation and should not be stored.Store between 15ºC and 30ºC (59ºF-86ºF).665490                                     C98-25 (Rev. 6/98)Distributed byNovartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936©1998 NovartisVialsThe reconstituted solution should be used upon preparation and should not be stored.Store between 15ºC and 30ºC (59ºF-86ºF).665490                                     C98-25 (Rev. 6/98)Distributed byNovartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936©1998 NovartisVialsThe reconstituted solution should be used upon preparation and should not be stored.Store between 15ºC and 30ºC (59ºF-86ºF).665490                                     C98-25 (Rev. 6/98)Distributed byNovartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936©1998 NovartisVialsThe reconstituted solution should be used upon preparation and should not be stored.Store between 15ºC and 30ºC (59ºF-86ºF).665490                                     C98-25 (Rev. 6/98)Distributed byNovartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936©1998 NovartisVialsThe reconstituted solution should be used upon preparation and should not be stored.Store between 15ºC and 30ºC (59ºF-86ºF).665490                                     C98-25 (Rev. 6/98)Distributed byNovartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936©1998 Novartis


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Regitine produces an alpha-adrenergic block of relatively short duration. It also has direct, but less marked, positive inotropic and chronotropic effects on cardiac muscle and vasodilator effects on vascular smooth muscle.

Regitine has a half-life in the blood of 19 minutes following intravenous administration. Approximately 13% of a single intravenous dose appears in the urine as unchanged drug.

Non-Clinical Toxicology
Myocardial infarction, history of myocardial infarction, coronary insufficiency, angina, or other evidence suggestive of coronary artery disease; hypersensitivity to phentolamine or related compounds.

Myocardial infarction, cerebrovascular spasm, and cerebrovascular occlusion have been reported to occur following the administration of Regitine, usually in association with marked hypotensive episodes.

For screening tests in patients with hypertension, the generally available urinary assay of catecholamines or other biochemical assays have largely replaced the Regitine and other pharmacological tests for reasons of accuracy and safety. None of the chemical or pharmacological tests is infallible in the diagnosis of pheochromocytoma. The Regitine blocking test is not the procedure of choice and should be reserved for cases in which additional confirmatory evidence is necessary and the relative risks involved in conducting the test have been considered.

See DOSAGE AND ADMINISTRATION, Diagnosis of pheochromocytoma,.

Tachycardia and cardiac arrhythmias may occur with the use of Regitine or other alpha-adrenergic blocking agents. When possible, administration of cardiac glycosides should be deferred until cardiac rhythm returns to normal.

Acute and prolonged hypotensive episodes, tachycardia, and cardiac arrhythmias have been reported. In addition, weakness, dizziness, flushing, orthostatic hypotension, nasal stuffiness, nausea, vomiting, and diarrhea may occur.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).